Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies

Clinical Infectious Diseases

Volumn 43, Issue 7, 2006, Pages 869-880

  Small, Lorne N ^a   Lau, Joseph ^a   Snydman, David R ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR; IMMUNOGLOBULIN; VALACICLOVIR; ANTIVIRUS AGENT;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; EMBASE; EVALUATION; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; INFECTION RISK; INTERMETHOD COMPARISON; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MORTALITY; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PREEMPTIVE THERAPY; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOM EFFECTS MODEL; RISK ASSESSMENT; COMPARATIVE STUDY; CYTOMEGALIC INCLUSION BODY DISEASE; PREVENTIVE MEDICINE;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; PREVENTIVE MEDICINE;

EID: 33748652453     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/507337     Document Type: Article

References (56)

1. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990; 12(Suppl 7):S754-66.
2. Stratta RJ, Shaeffer MS, Markin RS, et al. Cytomegalovirus infection and disease after liver transplantation: an overview. Dig Dis Sci 1992; 37:673-88.
3. Noble S, Faulds D. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 1998; 56:115-46.
4. Jassal SV, Roscoe JM, Zaltzman JS, et al. Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol 1998; 9:1697-708.
5. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis 2001; 32:742-51.
6. Dickenmann MJ, Kabulbayev K, Steiger J, Cathomas G, Reusser P, Tamm M. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection. Clin Microbiol Infect 2004; 10:337-9.
7. Said T, Nampoory MR, Johny KV, et al. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies. Transplant Proc 2004; 36:1847-9.
8. Vila A, Guirado LL, Balius A, et al. Acyclovir prophylaxis of cytomegalovirus disease in kidney transplant recipients. Transplant Proc 1999; 31:2335-6.
9. Bertoni E, Rosati A, Zanazzi M, et al. Cytomegalovirus disease prophylaxis in renal transplantation by high dose oral acyclovir: efficacy and limits. Transplant Proc 1998; 30:2094.
10. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5:218-27.
11. Hart GD, Paya CV. Prophylaxis for CMV should now replace preemptive therapy in solid organ transplantation. Rev Med Virol 2001; 11:73-81.
12. Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11:83-6.
13. Jung C, Engelmann E, Borner K, Offermann G. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation. Transplant Proc 2001; 33:3621-3.
14. Couchoud C, Cucherat M, Haugh M, Pouteil-Noble C. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis. Transplantation 1998; 65:641-7.
15. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365:2105-15.
16. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143:870-80.
17. Snydman DR. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis. Clin Infect Dis 2005; 40:709-12.
18. Cochrane Central Registry of Controlled Clinical Trials, 2nd quarter, 2005. Cochrane Library. Chichester, UK: Wiley, 2005.
19. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess 2005; 9:1-148.
20. Lim E, Ali Z, Ali A, et al. Indirect comparison meta-analysis of aspirin therapy after coronary surgery. BMJ 2003; 327:1309.
21. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J 2003; 326:472.
22. Aguado J, Gomez-Sanchez M, Lumbreras C, et al. Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrob Agents Chemother 1995; 39:1643-5.
23. Ahsan N, Holman M, Sonderbye L, Langhoff E, Yang H. Oral ganciclovir in the prevention of cytomegalovirus infection in postkidney transplant "CMV at risk" recipients: a controlled, comparative study of two regimens (750 mg bid and 500 mg bid). Transplant Proc 1998; 30:1383-5.
24. Ahsan N, Holman M, Yang H. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Clin Transplant 1997; 11:633-9.
25. Badley A, Seaberg E, Porayko M, et al. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir, NIDDK Liver Transplantation Database. Transplantation 1997; 64:66-73.
26. Brennan D, Garlock K, Singer G, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of CMV in renal transplant recipients. Transplantation 1997; 64:1843-6.
27. Cohen A, O'Grady J, Sutherland S, Sallie R, Tan K, Williams R. Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults. J Med Virol 1993; 40:5-9.
28. Flechner S, Avery R, Fisher R, et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998; 66:1682-8.
29. Gane E, Saliba F, Valdecasas G, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral ganciclovir International Transplantation Study Group. Lancet 1997; 350:1729-33.
30. King S, Superina R, Andrews W, et al. Randomized comparison of ganciclovir plus intravenous immune globulin (IVIG) with IVIG alone for prevention of primary cytomegalovirus disease in children receiving liver transplants. Clin Infect Dis 1997; 25:1173-9.
31. Leray H, Mourad G, Chong G, Segondy M, Mion C. Prophylactic treatment of cytomegalovirus primary infection with ganciclovir in renal transplant recipients. Transplant Proc 1995; 27:2448.
32. Macdonald P, Keogh A, Marshman D, et al. A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation. J Heart Lung Transplant 1995; 14:32-8.
33. Merigan T, Renlund D, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326:1182-6.
34. Pouteil-Noble C, Megas F, Chapuis F, et al. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial. Transplant Proc 1996; 28:2811.
35. Reischig T, Opatrny KJ, Bouda M, Treska V, Jindra P, Svecova M. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Transpl Int 2002; 15:615-22.
36. Rondeau E, Bourgeon B, Peraldi M, et al. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1993; 8:858-62.
37. Rubin R, Kemmerly S, Conti D, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000; 2:112-7.
38. Winston DJ, Busuttil RW. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 2003; 75:229-33.
39. Brennan D, Garlock K, Lippmann B, et al. Polymerase chain reaction-triggered preemptive or deferred therapy to control CMV-associated morbidity and costs in renal transplant patients. Transplant Proc 1997; 29:809-11.
40. Koetz A, Delbruck R, Furtwangler A, et al. Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective, double-blind, placebo-controlled study. Transplantation 2001; 72:1325-7.
41. Paya C, Wilson J, Espy M, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185:854-60.
42. Rayes N, Oettle H, Schmidt C, et al. Preemptive therapy in CMV-antigen positive patients after liver transplantation-a prospective trial. Ann Transplant 1999; 4:12-7.
43. Rayes N, Seehofer D, Schmidt C, et al. Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation. Transplantation 2001; 72:881-5.
44. Razonable R, van Cruijsen H, Brown R, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003; 187:1801-8.
45. Sagedal S, Nordal K, Hartmann A, et al. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant 2003; 18:1899-908.
46. Singh N, Yu V, Mieles L, Wagener M, Miner R, Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients: a randomized trial. Ann Intern Med 1994; 120:375-81.
47. Torre-Cisneros J, Madueno J, Herrero C, et al. Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients. Clin Microbiol Infect 2002; 8:773-80.
48. Meyer-Koenig U, Weidmann M, Kirste G, Hufert FT. Cytomegalovirus infection in organ-transplant recipients: diagnostic value of pp65 antigen test, qualitative polymerase chain reaction (PCR) and quantitative Taqman PCR. Transplantation 2004; 77:1692-8.
49. Seehofer D, Meisel H, Rayes N, et al. Prospective evaluation of the clinical utility of different methods for the detection of human cytomegalovirus disease after liver transplantation. Am J Transplant 2004; 4:1331-7.
50. Akalin E, Sehgal V, Ames S, et al. Cytomegaloviras disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3:731-5.
51. Humar A, Kumar D, Preiksaitis J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005; 5:1462-8.
52. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611-20.
53. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005; 79:85-90.
54. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004; 4:1635-42.
55. Tang JL, Liu JL. Misleading funnel plot for detection of bias in meta-analysis. J Clin Epidemiol 2000; 53:477-84.
56. Terrin N, Schmid CH, Lau J. In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias. J Clin Epidemiol 2005; 58:894-901.